FDA Expected to Authorize Moderna and Pfizer Vaxes for Children Under Five; White House Announces Covid-19 Vaccine Rollout (June 12, 2022)

On June 12, 2022, U.S. Food and Drug Administration (FDA) staff reported that the Pfizer COVID-19 three-shot vaccine regimen is effective at preventing symptomatic disease in children 6 months through 4 years-old with no new safety concerns. This comes on the heels of a June, 10, 2022 announcement by FDA staff reviewers who provided documentation that Moderna’s Covid-19 two-shot vaccine generated a similar immune response in the children than those observed in adults in previous trials and appears safe and effective for use in children aged 6 months to 17 years old.  

This week, a committee of scientists are expected to meet to vote on whether to recommend authorization for use of the two vaccines.

Previously, on June 9th the White House announced a highly anticipated Covid-19 vaccine rollout plan for children under five years-old.
The administration “has made 10 million vaccine doses available for states, Tribes, territories, community health centers, federal pharmacy partners, and others to pre-order,” according to a White House fact sheet. It is partnering with those entities to ship and distribute vaccines across the country following full FDA authorization of vaccines from Pfizer and Moderna.
The first vaccinations could start “as early as the week of June 20th —with the program ramping up over time as more doses are delivered and more appointments become available,” according to the fact sheet.
CNN previously reported Covid-19 vaccination shots for the youngest Americans could begin as soon as June 21.

To view the fact sheet, click here.

For more info, click here.

Sources: NBC News, The Wall Street Journal, and CNN.